3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Squamous Cell
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumors
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
PD-L1-selected Solid Tumors
1
Glioblastoma
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Advanced Rare Malignant Solid Neoplasm
1
Interventions
tislelizumab
1
pembrolizumab
1
patritumab deruxtecan
1
leronlimab
1
lenvatinib
1
atezolizumab
1
Tiragolumab
1
Radiotherapy
1
Cryosurgery
1
3-amino-1-methyl-3-(4-(3-phenyl-5H- imidazo(1,2-c)pyrido(3,4-e)(1,3)oxazin-2-yl)phenyl)cyclobutanol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Solid Tumor, Adult
×
Tiragolumab
×
Clear all
NCT06003621
2024-11-15
MoST-TAP
Omico
Phase 2
Recruiting
96 enrolled